GB Sciences, Inc. GBLX
Set alert
0.00 USD 0.00 0.00%
At close · Oct 30
0.0003 Day range 0.0003
0.0001 52-week range 0.50015
- YTD
- -80.00%
- 1 year
- -66.67%
- Open
- 0.0003
- Prev close
- 0.0001
- Mkt cap
- 40.71K
- Vol
- 31.00K
- Avg vol
- 56.72K
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 0.0003
- High
- 0.0003
3M chart
Signals (18)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 3, 2026 | 2 months ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
News
- GB Sciences (OTCMKTS:GBLX) Stock Passes Above 50 Day Moving Average – What’s Next?
- Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation
- Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference
- GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform
- GB Sciences Using AI Technology in Plant-Based Drug Discovery Research
- GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President
- GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
- GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Wednesday
Your note
Sign in to keep a note on GBLX — it syncs with the Stock Master app.